Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study ; volume:22 ; number:1 ; day:25 ; month:3 ; year:2023 ; pages:1-14 ; date:12.2023
Cardiovascular diabetology ; 22, Heft 1 (25.3.2023), 1-14, 12.2023
- Urheber
-
Piccini, Sara
Favacchio, Giuseppe
Panico, Cristina
Morenghi, Emanuela
Folli, Franco
Mazziotti, Gherardo
Lania, Andrea Gerardo
Mirani, Marco
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12933-023-01800-z
- URN
-
urn:nbn:de:101:1-2023081310442912115043
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Piccini, Sara
- Favacchio, Giuseppe
- Panico, Cristina
- Morenghi, Emanuela
- Folli, Franco
- Mazziotti, Gherardo
- Lania, Andrea Gerardo
- Mirani, Marco
- SpringerLink (Online service)
Ähnliche Objekte (12)
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Time-Dependent Effects of Unemployment Benefits
Potential implications of long-acting GLP-1 receptor agonists for critically ill
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency
GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence
Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Time-Dependent Effects of Unemployment Benefits
Potential implications of long-acting GLP-1 receptor agonists for critically ill
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency
GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence
Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Time-Dependent Effects of Unemployment Benefits
Potential implications of long-acting GLP-1 receptor agonists for critically ill
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency
GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence